• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4598975)   Today's Articles (2517)   Subscriber (49356)
For: Russo R, Capurro N, Cozzani E, Parodi A. Use of Dupilumab in Bullous Pemphigoid: Where Are We Now? J Clin Med 2022;11:3367. [PMID: 35743438 DOI: 10.3390/jcm11123367] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 06/07/2022] [Accepted: 06/10/2022] [Indexed: 02/06/2023]  Open
Number Cited by Other Article(s)
1
Martinez DDAES, Periquito ADFS, Roa GG, Lupi JP, Treu CM, Lupi O. Bullous pemphigoid successfully treated with Dupilumab. An Bras Dermatol 2024:S0365-0596(24)00115-6. [PMID: 38876965 DOI: 10.1016/j.abd.2023.08.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 07/16/2023] [Accepted: 08/02/2023] [Indexed: 06/16/2024]  Open
2
Hansen I, Gebhardt C, Booken N, Schneider SW. Erfolgreiche Behandlung eines Checkpoint‐Inhibitor‐assoziierten bullösen Pemphigoids mit Dupilumab bei Angiosarkom. J Dtsch Dermatol Ges 2024;22:587-590. [PMID: 38574016 DOI: 10.1111/ddg.15340_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Accepted: 11/16/2023] [Indexed: 04/06/2024]
3
Hansen I, Gebhardt C, Booken N, Schneider SW. Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma. J Dtsch Dermatol Ges 2024;22:587-589. [PMID: 38379256 DOI: 10.1111/ddg.15340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Accepted: 11/16/2023] [Indexed: 02/22/2024]
4
Hu L, Huang R, Jiang F, You S, Wu Q. Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study. Immun Inflamm Dis 2023;11:e924. [PMID: 37506153 PMCID: PMC10367446 DOI: 10.1002/iid3.924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 05/05/2023] [Accepted: 06/15/2023] [Indexed: 07/30/2023]  Open
5
Savoldy MA, Tadicherla T, Moureiden Z, Ayoubi N, Baldwin BT. The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab. Cureus 2022;14:e30541. [DOI: 10.7759/cureus.30541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/21/2022] [Indexed: 11/05/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA